Sponsor	Phase
University of New Mexico	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
B Braun	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER	calcium chloride; dextrose; magnesium chloride; potassium chloride; sodium acetate; sodium chloride; sodium citrate	INJECTABLE;INJECTION	018269-002	Jan 17, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 8, 2026

ISOLYTE E with Dextrose 5% is a mature, low-priced intravenous electrolyte product whose financial performance depends on hospital utilization, manufacturing reliability, contract pricing, and IV-fluid supply conditions rather than patent exclusivity. Public filings do not report standalone sales for this product. Its commercial outlook is stable in normal supply conditions, with upside during IV-fluid shortages and margin pressure from commodity pricing, labor, packaging, and regulatory-compliance costs.

ISOLYTE E With Dextrose 5% Market Dynamics and Financial Trajectory

What is ISOLYTE E With Dextrose 5%?

ISOLYTE E in 5% Dextrose is a sterile intravenous solution that supplies water, dextrose, and electrolytes. It is used when patients require parenteral fluid, carbohydrate, and electrolyte replacement. The product is supplied in a plastic container for hospital and institutional use.

The product belongs to the mature large-volume parenteral, or LVP, market. LVP products include dextrose solutions, sodium chloride solutions, balanced electrolyte solutions, lactated Ringer's, and premixed specialty fluids.

Its principal commercial characteristics are:

Attribute	Assessment
Therapeutic category	Intravenous fluid and electrolyte replacement
Dosage form	Sterile injectable solution
Administration	Intravenous infusion
Product type	Mature multisource hospital injectable
Core customers	Hospitals, ambulatory surgery centers, emergency departments, and institutional pharmacies
Main demand driver	Inpatient and acute-care utilization
Differentiation	Electrolyte composition combined with 5% dextrose
Commercial risk	Supply interruption and manufacturing cost exposure
Patent dependence	Low
Biosimilar exposure	None

The product is clinically substitutable with other electrolyte-containing dextrose solutions in some settings, but substitution depends on electrolyte composition, patient condition, physician preference, hospital formularies, and inventory availability.

What is the FDA regulatory status of ISOLYTE E?

ISOLYTE E is an FDA-regulated prescription intravenous drug product marketed under an approved product-specific regulatory framework and described in FDA labeling available through DailyMed. The label establishes its composition, indications, warnings, contraindications, dosage, administration, and container information.[1]

Important regulatory issues include:

Sterility assurance.
Container-closure integrity.
Particulate and endotoxin control.
Stability throughout the labeled shelf life.
Accurate electrolyte and dextrose concentration.
Manufacturing-site compliance with current good manufacturing practice.
Controls over plastic container materials and extractables and leachables.

Large-volume injectable products have a higher manufacturing and quality burden than ordinary oral generics. A failed sterility investigation, filling-line problem, raw-material shortage, or container defect can remove supply from the market even when demand remains stable.

FDA’s drug-shortage database has repeatedly identified injectable fluids as a supply-sensitive category. Shortages can affect dextrose solutions, sodium chloride products, balanced electrolyte solutions, and other hospital fluids because production is concentrated among a limited number of manufacturers and facilities.[2]

What is the Orange Book status of ISOLYTE E?

ISOLYTE E is not an Orange Book-driven branded product in the same commercial sense as a patented small-molecule medicine. The Orange Book is primarily relevant to approved drug products with listed patents, pediatric exclusivity, and generic-substitution information.[3]

For ISOLYTE E, the commercial analysis is more likely to involve:

The approved application or product listing.
NDC and package-level marketing status.
Manufacturer and facility authorization.
FDA inspection history.
Product availability.
Hospital purchasing contracts.

No material patent-based exclusivity strategy is apparent for the basic electrolyte-and-dextrose formulation. The product has been commercially established for many years, and its composition is based on conventional clinical fluid therapy rather than a new molecular entity.

What patents protect ISOLYTE E with Dextrose 5%?

The core product has limited patent protection. The relevant intellectual-property position is likely divided into four categories:

IP category	Commercial relevance
Active ingredient composition	Low; electrolytes and dextrose are established ingredients
Method-of-use patents	Low; fluid and electrolyte replacement uses are conventional
Formulation patents	Limited; concentration and electrolyte combinations may be disclosed in older technical or regulatory filings
Container and manufacturing technology	Moderate operational value; plastic materials, filling systems, sterilization, and packaging processes can be protected independently

Any relevant patent would need to be assessed against the precise formulation, package configuration, manufacturing process, and jurisdiction. The commercial barrier is not likely to be a patent blocking generic entry. It is the cost and complexity of producing sterile injectable fluids at scale while maintaining reliable supply.

Does ISOLYTE E face Paragraph IV challenges?

Paragraph IV litigation is unlikely to be a central risk for this product. Paragraph IV challenges are directed at patents listed in the FDA Orange Book against an approved reference drug. A mature electrolyte solution with little or no relevant listed patent protection generally does not create the same litigation pathway as a patented branded medicine.

Potential competitors can enter through applicable abbreviated or other FDA approval pathways if they meet the requirements for equivalence, quality, manufacturing, and labeling. Competition is therefore more likely to arise from supply contracts and manufacturing capacity than from a patent challenge.

Is there biosimilar risk for ISOLYTE E?

There is no biosimilar risk. ISOLYTE E is a chemically defined sterile solution, not a biologic licensed under the Public Health Service Act. Competitive products would be generics, therapeutic alternatives, or other approved intravenous fluids rather than biosimilars.

How large is the market for ISOLYTE E?

The relevant market is the U.S. hospital LVP market. Public companies generally report IV fluids within broad pharmaceutical, hospital-products, or medical-products segments. They do not break out revenue for an individual electrolyte solution such as ISOLYTE E.

Demand is structurally defensive because intravenous fluids are used across:

Surgical procedures.
Emergency medicine.
Intensive-care treatment.
Dehydration and electrolyte replacement.
Perioperative care.
Drug reconstitution and dilution.
Inpatient maintenance therapy.

Volume growth is linked to hospital admissions, procedure volumes, emergency-department activity, and institutional purchasing. Price growth is limited by group purchasing organization contracts, hospital formularies, and the availability of substitute fluids.

The market has a two-tier economic structure:

Normal conditions produce predictable but low-margin recurring demand.
Supply disruptions can create temporary price leverage, allocation, and accelerated purchasing.

The second condition can lift revenue without improving long-term market economics. Shortage-related gains may be offset by overtime, expedited freight, validation work, facility remediation, and regulatory scrutiny.

What drives the financial trajectory of ISOLYTE E?

A product-level revenue forecast is not available from public company disclosures because ISOLYTE E sales are not separately reported. Its financial trajectory can be assessed through operating drivers.

Driver	Effect on revenue	Effect on margin
Hospital admissions	Positive	Generally neutral
Surgical volume	Positive	Generally neutral
IV-fluid shortages	Strong short-term positive	Mixed because costs rise
Contract renewals	Can preserve volume	Often negative for price
Plastic resin costs	Neutral to modestly negative	Negative
Labor and quality costs	Neutral	Negative
New manufacturing capacity	Positive over time	Initially negative, later positive
Product substitution	Negative	Negative
Regulatory remediation	Negative	Strongly negative
Allocation conditions	Positive for available supply	Mixed

The product’s likely long-term profile is a mature-volume, low-growth business. Revenue should track institutional utilization rather than prescription growth. Margin performance will depend on manufacturing scale, plant utilization, product mix, and the manufacturer’s ability to recover input-cost increases through contracts.

Which companies compete with ISOLYTE E?

Competition comes from manufacturers of large-volume parenterals and from clinically substitutable products. Relevant competitors can include Baxter, B. Braun, ICU Medical, and other FDA-authorized injectable-fluid suppliers, depending on product availability and the specific electrolyte composition.

The closest alternatives may include:

Balanced electrolyte solutions without dextrose.
Dextrose-containing saline solutions.
Lactated Ringer’s with dextrose.
Plasma-Lyte or Normosol products.
Electrolyte replacement fluids selected according to patient chemistry.
Hospital-compounded or pharmacy-prepared alternatives in limited circumstances.

The competitive decision is usually made by hospital pharmacy and supply-chain departments. Price is important, but supply reliability, shortage history, manufacturing quality, package design, and contract terms can determine product selection.

How does ISOLYTE E compare with standard dextrose or saline products?

ISOLYTE E has a broader electrolyte profile than plain 5% dextrose and differs from standard sodium chloride products in both composition and clinical use. That gives it a narrower but clinically relevant position.

Product class	Main commercial advantage	Main limitation
5% dextrose	Low-cost carbohydrate and water source	Does not provide a balanced electrolyte profile
0.9% sodium chloride	Broad availability and familiarity	Higher sodium and chloride load
Lactated Ringer’s	Common balanced crystalloid	Not interchangeable in every clinical circumstance
Balanced electrolyte with dextrose	Combines fluid, carbohydrate, and multiple electrolytes	More complex manufacturing and narrower purchasing demand
ISOLYTE E	Established electrolyte-plus-dextrose option	Mature product with limited pricing power

Clinical substitution is not automatic. Hospitals assess electrolyte content, glucose load, patient-specific contraindications, and the risk of fluid or electrolyte imbalance before switching products.

What manufacturing and intellectual-property barriers affect ISOLYTE E?

Manufacturing is the main barrier to entry. A competitor must establish:

Validated compounding and filling processes.
Sterile manufacturing capacity.
Reliable supplies of pharmaceutical-grade dextrose and electrolytes.
Qualified plastic containers and overwrap systems.
Automated inspection and particulate-control systems.
Stability data.
Container-closure integrity.
Release testing and batch documentation.
FDA-compliant quality systems.

Plastic-container products also require control of container materials, sealing, sterilization compatibility, and shipping performance. A low unit price increases the importance of plant scale and throughput.

This structure favors established manufacturers with high-volume facilities. It discourages entry based solely on the theoretical simplicity of the formulation. A competitor may be able to make the solution chemically, yet still face substantial cost and regulatory barriers in producing it consistently at commercial scale.

What litigation or settlement agreements affect ISOLYTE E?

Patent litigation and settlement agreements are not expected to be major commercial factors for ISOLYTE E. The product lacks the profile of a high-value patented therapy with repeated Paragraph IV challenges.

The more relevant legal and regulatory exposures are:

Product-liability claims.
Manufacturing-defect claims.
Failure-to-warn allegations.
Contract disputes with hospitals or group purchasing organizations.
FDA warning letters or inspection findings.
Product recalls.
Supply agreements and allocation disputes.

No material branded-generic settlement structure is central to the product’s market outlook. Commercial agreements are more likely to concern distribution, hospital contracting, and supply allocation.

When does ISOLYTE E lose exclusivity?

ISOLYTE E is already a mature product. Its commercial position does not depend on a near-term patent cliff or an exclusivity expiration date.

The relevant timing framework is:

Timing issue	Assessment
New chemical entity exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	Not a central commercial factor
Orange Book patent cliff	Not a central risk
Generic competition	Established or readily possible under applicable FDA pathways
Current exclusivity value	Minimal
Supply-related value	Material during shortages

The product can retain sales despite weak exclusivity because hospitals need dependable inventory. In this category, supply continuity can be more valuable than patent protection.

What generic launch risks exist for ISOLYTE E?

Generic entry risk is moderate from a volume perspective and low from a patent-litigation perspective.

A new entrant could pressure price if it offers:

Equivalent clinical composition.
Reliable supply.
Competitive packaging.
Sufficient production capacity.
Favorable hospital-contract pricing.
A clean regulatory and inspection record.

Entry would not automatically displace the incumbent. Hospitals may maintain multiple suppliers because shortages are operationally disruptive. A supplier with excess capacity can win share even without a meaningful product patent.

The largest risk to the incumbent is sustained price competition combined with a competitor that can guarantee supply. The largest risk to a new entrant is failure to maintain manufacturing continuity.

What is the expected financial trajectory?

The base-case trajectory is stable volume with limited organic price growth. Revenue may rise modestly with hospital utilization and periodic price adjustments, but the product is unlikely to produce pharmaceutical-style growth.

Base case

Stable institutional demand.
Low-to-mid single-digit nominal revenue growth at most, depending on contracts and supply conditions.
Persistent margin pressure from labor, packaging, and quality costs.
No meaningful patent-driven price protection.

Upside case

Industry-wide IV-fluid shortages.
Competitor manufacturing outages.
Successful capacity expansion.
Improved contract pricing.
Higher hospital and surgical utilization.

Downside case

New competitor capacity.
Contract price reductions.
Substitution toward other balanced fluids.
Manufacturing interruption.
Recall or regulatory remediation.
Declining hospital utilization.

The most important investment variable is manufacturing reliability rather than exclusivity duration. An owner with diversified sterile-injectable capacity can extract greater value from the product than an owner operating a single constrained facility.

Key Takeaways

ISOLYTE E with Dextrose 5% is a mature sterile intravenous electrolyte product.
Its market is driven by hospitals, surgery, emergency care, and institutional fluid demand.
Product-level revenue is not separately disclosed in public filings.
Patent exclusivity is not the primary commercial asset.
Paragraph IV, biosimilar, and branded-generic settlement risks are limited.
FDA compliance, sterile manufacturing, plastic-container quality, and supply continuity are the main barriers to competition.
Shortages can create temporary revenue and pricing upside but often increase operating costs.
The expected financial profile is stable, low-growth, and margin-sensitive.
Competitive advantage depends on manufacturing scale, regulatory execution, and hospital supply contracts.

FAQs

Is ISOLYTE E the same as 5% dextrose in water?

No. ISOLYTE E contains dextrose plus electrolytes. Plain 5% dextrose in water does not provide the same electrolyte composition and is not automatically interchangeable.

Does ISOLYTE E require a prescription?

Yes. It is a prescription sterile injectable product administered in clinical settings under professional supervision.[1]

Can hospitals substitute Lactated Ringer’s for ISOLYTE E?

Not universally. Substitution depends on electrolyte composition, glucose content, patient factors, physician orders, and hospital formulary policy.

Is ISOLYTE E vulnerable to a manufacturing shutdown?

Yes. Large-volume sterile injectables are vulnerable to plant outages because production is concentrated and replacement capacity is limited. A shutdown can create allocation and shortage pressure even when the underlying formulation is mature.[2]

Is ISOLYTE E an attractive patent-licensing asset?

Generally, no. Its value is more closely tied to FDA-approved manufacturing capacity, supply contracts, quality systems, and distribution than to exclusive patent rights.

References

DailyMed. (n.d.). ISOLYTE E injection, solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations, 43rd edition. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

Which patents cover Isolyte E W/ Dextrose 5% In Plastic Container, and when can generic versions of Isolyte E W/ Dextrose 5% In Plastic Container launch?

AI Deep Research

Questions you can ask:

Summary for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

Recent Clinical Trials for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER

US Patents and Regulatory Information for ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER